Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.neulandlabs.com | |
Market Cap | 1,819.92 Cr. | |
Enterprise Value(EV) | 1,981.91 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 64.80 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 21.67 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.78 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 687.25 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 2.04 | Calculated using Price: 1,404.05 |
Dividend Yield | 0.35 | Period Ending 2022-03 |
No. of Shares Subscribed | 1.28 Cr. | 12,829,889 Shares |
FaceValue | 10 | |
Company Profile | ||
Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients. Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe. |
1 Day |
|
-3.20% |
1 Week |
|
-8.81% |
1 Month |
|
-15.85% |
3 Month |
|
-4.93% |
6 Month |
|
+8.57% |
1 Year |
|
-4.77% |
2 Year |
|
+9.12% |
5 Year |
|
+66.97% |
10 Year |
|
+1019.39% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 24.14 | 11.24 | 15.64 | 22.34 | 5.02 | 3.48 | 2.30 | 10.79 | 7.85 | |
Return on Capital Employed (%) | 18.99 | 15.75 | 18.57 | 15.98 | 4.07 | 3.99 | 7.85 | 12.81 | 9.44 | |
Return on Assets (%) | 5.89 | 3.20 | 5.23 | 6.65 | 1.23 | 1.49 | 1.37 | 6.31 | 4.71 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 124 | 161 | 187 | 546 | 558 | 699 | 710 | 786 | 841 | 883 | |
Non Curr. Liab. | 52 | 55 | 69 | 54 | 146 | 104 | 163 | 170 | 180 | 164 | |
Curr. Liab. | 307 | 295 | 268 | 286 | 367 | 327 | 358 | 369 | 363 | 378 | |
Minority Int. | 0 | 0 | |||||||||
Equity & Liab. | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,424 | |
Non Curr. Assets | 196 | 196 | 210 | 511 | 624 | 677 | 716 | 775 | 801 | 805 | |
Curr. Assets | 288 | 316 | 314 | 375 | 447 | 453 | 515 | 550 | 583 | 620 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,424 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 466 | 469 | 510 | 579 | 527 | 667 | 763 | 937 | 951 | 1,007 | |
Other Income | 3 | 1 | 2 | 1 | 5 | 3 | 4 | 16 | 2 | 3 | |
Total Income | 469 | 470 | 512 | 580 | 532 | 670 | 767 | 953 | 953 | 1,011 | |
Total Expenditure | -395 | -403 | -430 | -473 | -477 | -608 | -661 | -790 | -808 | -838 | |
PBIDT | 74 | 67 | 82 | 108 | 55 | 62 | 106 | 163 | 145 | 172 | |
Interest | -25 | -27 | -24 | -21 | -19 | -16 | -22 | -18 | -14 | -12 | |
Depreciation | -15 | -15 | -16 | -19 | -22 | -26 | -31 | -40 | -49 | -51 | |
Taxation | -8 | -9 | -15 | -20 | -2 | -4 | -37 | -25 | -18 | -26 | |
Exceptional Items | |||||||||||
PAT | 27 | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 83 | |
Minority Interest | 0 | 0 | 0 | ||||||||
Share Associate | |||||||||||
Other Related Items | |||||||||||
Consolidated Net Profit | 27 | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 83 | |
Adjusted EPS | 33 | 18 | 31 | 53 | 14 | 13 | 13 | 63 | 50 | 64 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 26 | 49 | 13 | 45 | 39 | 11 | 70 | 57 | 189 | 59 | |
Cash Fr. Inv. | -7 | -10 | -14 | -20 | -42 | -116 | -77 | -49 | -84 | -94 | |
Cash Fr. Finan. | -20 | -39 | 1 | -24 | 0 | 105 | 12 | -5 | -114 | 38 | |
Net Change | -1 | 0 | 0 | 1 | -4 | 0 | 5 | 3 | -9 | 3 | |
Cash & Cash Eqvt | 1 | 1 | 1 | 2 | 3 | 3 | 8 | 11 | 2 | 5 |
Fri, 20 Jan 2023
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2022 NEULAND LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2023 inter alia to consider and approve The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2022 |
Thu, 05 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 |
Fri, 30 Dec 2022
Closure of Trading Window Closure of Trading Window |
Mon, 30 Jan 2023 |
|
|
|
|
|